Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information |
Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss):
Supplemental Equity
The Company has declared cash dividends per share of $0.08 and $0.24 in the quarter and nine months ended March 31, 2025 and 2024, respectively.
Consolidated Changes in Equity (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bio-Techne Shareholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
Common Stock |
|
Paid-in |
|
Retained |
|
Comprehensive |
|
|
|
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Loss |
|
Total |
Balances at June 30, 2024 |
|
158,216 |
|
$ |
1,582 |
|
$ |
820,337 |
|
$ |
1,325,247 |
|
$ |
(78,316) |
|
$ |
2,068,850 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
33,600 |
|
|
|
|
|
33,600 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
18,229 |
|
|
18,229 |
Common stock issued for exercise of options |
|
577 |
|
|
6 |
|
|
23,224 |
|
|
(2,338) |
|
|
|
|
|
20,892 |
Common stock issued for restricted stock awards |
|
50 |
|
|
1 |
|
|
1 |
|
|
(2,646) |
|
|
|
|
|
(2,644) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,688) |
|
|
|
|
|
(12,688) |
Stock-based compensation expense |
|
|
|
|
|
|
|
10,146 |
|
|
|
|
|
|
|
|
10,146 |
Common stock issued to employee stock purchase plan |
|
35 |
|
|
0 |
|
|
2,227 |
|
|
|
|
|
|
|
|
2,227 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
38 |
|
|
|
|
|
|
|
|
38 |
Balances at September 30, 2024 |
|
158,878 |
|
$ |
1,589 |
|
$ |
855,973 |
|
$ |
1,341,175 |
|
$ |
(60,087) |
|
$ |
2,138,650 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
34,890 |
|
|
|
|
|
34,890 |
Other comprehensive (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
(25,563) |
|
|
(25,563) |
Share repurchases |
|
(1,118) |
|
|
(11) |
|
|
|
|
|
(75,617) |
|
|
|
|
|
(75,628) |
Common stock issued for exercise of options |
|
132 |
|
|
1 |
|
|
5,183 |
|
|
(20) |
|
|
|
|
|
5,164 |
Common stock issued for restricted stock awards |
|
24 |
|
|
0 |
|
|
0 |
|
|
(993) |
|
|
|
|
|
(993) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,736) |
|
|
|
|
|
(12,736) |
Stock-based compensation expense |
|
|
|
|
|
|
|
14,335 |
|
|
|
|
|
|
|
|
14,335 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
373 |
|
|
|
|
|
|
|
|
373 |
Balances at December 31, 2024 |
|
157,916 |
|
$ |
1,579 |
|
$ |
875,864 |
|
$ |
1,286,699 |
|
$ |
(85,650) |
|
$ |
2,078,492 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
22,588 |
|
|
|
|
|
22,588 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
3,598 |
|
|
3,598 |
Share repurchases |
|
(1,489) |
|
|
(15) |
|
|
|
|
|
(100,031) |
|
|
|
|
|
(100,046) |
Common stock issued for exercise of options |
|
282 |
|
|
3 |
|
|
12,628 |
|
|
|
|
|
|
|
|
12,631 |
Common stock issued for restricted stock awards |
|
9 |
|
|
1 |
|
|
1 |
|
|
(291) |
|
|
|
|
|
(289) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,580) |
|
|
|
|
|
(12,580) |
Stock-based compensation expense |
|
|
|
|
|
|
|
11,355 |
|
|
|
|
|
|
|
|
11,355 |
Common stock issued to employee stock purchase plan |
|
43 |
|
|
0 |
|
|
2,241 |
|
|
|
|
|
|
|
|
2,241 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
35 |
|
|
|
|
|
|
|
|
35 |
Balances at March 31, 2025 |
|
156,761 |
|
$ |
1,568 |
|
$ |
902,124 |
|
$ |
1,196,385 |
|
$ |
(82,052) |
|
$ |
2,018,025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bio-Techne Shareholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
Common Stock |
|
Paid-in |
|
Retained |
|
Comprehensive |
|
|
|
|
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Loss |
|
Total |
Balances at June 30, 2023 |
|
157,642 |
|
$ |
1,576 |
|
$ |
721,543 |
|
$ |
1,309,461 |
|
$ |
(66,064) |
|
$ |
1,966,516 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
50,993 |
|
|
|
|
|
50,993 |
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,952) |
|
|
(11,952) |
Common stock issued for exercise of options |
|
633 |
|
|
6 |
|
|
12,877 |
|
|
(15,460) |
|
|
|
|
|
(2,577) |
Common stock issued for restricted stock awards |
|
47 |
|
|
1 |
|
|
0 |
|
|
(4,768) |
|
|
|
|
|
(4,767) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,654) |
|
|
|
|
|
(12,654) |
Stock-based compensation expense |
|
|
|
|
|
|
|
9,981 |
|
|
|
|
|
|
|
|
9,981 |
Common stock issued to employee stock purchase plan |
|
33 |
|
|
1 |
|
|
2,093 |
|
|
|
|
|
|
|
|
2,094 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
112 |
|
|
|
|
|
|
|
|
112 |
Balances at September 30, 2023 |
|
158,355 |
|
$ |
1,584 |
|
$ |
746,606 |
|
$ |
1,327,572 |
|
$ |
(78,016) |
|
$ |
1,997,746 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
27,465 |
|
|
|
|
|
27,465 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,355 |
|
|
14,355 |
Share repurchases |
|
(1,397) |
|
|
(14) |
|
|
|
|
|
(80,028) |
|
|
|
|
|
(80,042) |
Common stock issued for exercise of options |
|
157 |
|
|
1 |
|
|
4,914 |
|
|
(1,074) |
|
|
|
|
|
3,841 |
Common stock issued for restricted stock awards |
|
27 |
|
|
0 |
|
|
0 |
|
|
|
|
|
|
|
|
0 |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,559) |
|
|
|
|
|
(12,559) |
Stock-based compensation expense |
|
|
|
|
|
|
|
12,413 |
|
|
|
|
|
|
|
|
12,413 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
340 |
|
|
|
|
|
|
|
|
340 |
Balances at December 31, 2023 |
|
157,142 |
|
$ |
1,571 |
|
$ |
764,273 |
|
$ |
1,261,376 |
|
$ |
(63,661) |
|
$ |
1,963,559 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
49,059 |
|
|
|
|
|
49,059 |
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,646) |
|
|
(11,646) |
Common stock issued for exercise of options |
|
372 |
|
|
4 |
|
|
15,761 |
|
|
|
|
|
|
|
|
15,765 |
Common stock issued for restricted stock awards |
|
4 |
|
|
0 |
|
|
0 |
|
|
(168) |
|
|
|
|
|
(168) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,579) |
|
|
|
|
|
(12,579) |
Stock-based compensation expense |
|
|
|
|
|
|
|
8,053 |
|
|
|
|
|
|
|
|
8,053 |
Common stock issued to employee stock purchase plan |
|
36 |
|
|
1 |
|
|
2,251 |
|
|
|
|
|
|
|
|
2,252 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
80 |
|
|
|
|
|
|
|
|
80 |
Balances at March 31, 2024 |
|
157,554 |
|
$ |
1,576 |
|
$ |
790,418 |
|
$ |
1,297,688 |
|
$ |
(75,307) |
|
$ |
2,014,375 |
Accumulated Other Comprehensive Income
The components of Other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The accumulated balances related to each component of Other comprehensive income (loss) are summarized as follows:
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2025 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of December 31, 2024, net of tax |
|
$ |
5,030 |
|
$ |
(90,680) |
|
$ |
(85,650) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(3,079) |
|
|
4,807 |
|
|
1,728 |
Amounts reclassified out |
|
|
1,790 |
|
|
660 |
|
|
2,450 |
Total other comprehensive income (loss), before tax |
|
|
(1,289) |
|
|
5,467 |
|
|
4,178 |
Tax (expense)/benefit |
|
|
(424) |
|
|
(156) |
|
|
(580) |
Total other comprehensive income (loss), net of tax |
|
|
(1,713) |
|
|
5,311 |
|
|
3,598 |
Balance as of March 31, 2025, net of tax |
|
$ |
3,317 |
|
$ |
(85,369) |
|
$ |
(82,052) |
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2024 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of December 31, 2023 net of tax: |
|
$ |
8,842 |
|
$ |
(72,503) |
|
$ |
(63,661) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(1,626) |
|
|
(12,620) |
|
|
(14,246) |
Amounts reclassified out |
|
|
2,570 |
|
|
837 |
|
|
3,407 |
Total other comprehensive income (loss), before tax |
|
|
944 |
|
|
(11,783) |
|
|
(10,839) |
Tax (expense)/benefit |
|
|
(609) |
|
|
(198) |
|
|
(807) |
Total other comprehensive income (loss), net of tax |
|
|
335 |
|
|
(11,981) |
|
|
(11,646) |
Balance as of March 31, 2024, net of tax |
|
$ |
9,177 |
|
$ |
(84,484) |
|
$ |
(75,307) |
|
|
|
|
|
|
|
|
|
|
Nine months ended March 31, 2025 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of June 30, 2024, net of tax: |
|
$ |
8,102 |
|
$ |
(86,418) |
|
$ |
(78,316) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(9,778) |
|
|
(555) |
|
|
(10,333) |
Amounts reclassified out |
|
|
6,544 |
|
|
2,102 |
|
|
8,646 |
Total other comprehensive income (loss), before tax |
|
|
(3,234) |
|
|
1,547 |
|
|
(1,687) |
Tax (expense)/benefit |
|
|
(1,551) |
|
|
(498) |
|
|
(2,049) |
Total other comprehensive income (loss), net of tax |
|
|
(4,785) |
|
|
1,049 |
|
|
(3,736) |
Balance as of March 31, 2025, net of tax(1) |
|
$ |
3,317 |
|
$ |
(85,369) |
|
$ |
(82,052) |
|
|
|
|
|
|
|
|
|
|
Nine months ended March 31, 2024 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of June 30, 2023, net of tax: |
|
$ |
12,862 |
|
$ |
(78,926) |
|
$ |
(66,064) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(9,582) |
|
|
(7,368) |
|
|
(16,950) |
Amounts reclassified out |
|
|
7,729 |
|
|
2,372 |
|
|
10,101 |
Total other comprehensive income (loss), before tax |
|
|
(1,853) |
|
|
(4,996) |
|
|
(6,849) |
Tax (expense)/benefit |
|
|
(1,832) |
|
|
(562) |
|
|
(2,394) |
Total other comprehensive income (loss), net of tax |
|
|
(3,685) |
|
|
(5,558) |
|
|
(9,243) |
Balance as of March 31, 2024, net of tax(1) |
|
$ |
9,177 |
|
$ |
(84,484) |
|
$ |
(75,307) |
(1) The Company had a net deferred tax liability for its cash flow hedge of $1.0 million and $2.9 million as of March 31, 2025 and 2024, respectively.
Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge.
|